{"id":69585,"date":"2025-03-03T00:00:00","date_gmt":"2025-03-03T00:00:00","guid":{"rendered":"https:\/\/www.pharmacie-vezere.com\/promotions\/eikon-leve-pres-de-351-millions-de-dollars-pour-faire-progresser-des-traitements-contre-le-cancer-en-clinique\/"},"modified":"2025-03-03T00:00:00","modified_gmt":"2025-03-03T00:00:00","slug":"eikon-leve-pres-de-351-millions-de-dollars-pour-faire-progresser-des-traitements-contre-le-cancer-en-clinique","status":"publish","type":"post","link":"https:\/\/www.pharmacie-vezere.com\/promotions\/eikon-leve-pres-de-351-millions-de-dollars-pour-faire-progresser-des-traitements-contre-le-cancer-en-clinique\/","title":{"rendered":"Eikon l\u00e8ve pr\u00e8s de 351 millions de dollars pour faire progresser des traitements contre le cancer en clinique."},"content":{"rendered":"<p>Eikon a lev\u00e9 1,1 milliard de dollars depuis sa cr\u00e9ation en 2019. Cr\u00e9dit : Richard Drury via Getty Images.<\/p>\n<p>La soci\u00e9t\u00e9 de biotechnologie am\u00e9ricaine Eikon Therapeutics a lev\u00e9 350,7 millions de dollars pour faire progresser ses traitements contre le cancer. Son principal m\u00e9dicament, EIK1001, est en phase III d\u2019essais cliniques pour le m\u00e9lanome avanc\u00e9, combin\u00e9 avec le m\u00e9dicament Keytruda (pembrolizumab) de MSD. Un autre essai est en cours pour le cancer du poumon non \u00e0 petites cellules, qui devrait se terminer en 2026.<\/p>\n<p>Eikon a acquis les droits de d\u00e9veloppement de EIK1001 en rachetant des modulateurs immunitaires \u00e0 Seven and Eight Biotherapeutics en 2023. EIK1001 a montr\u00e9 des r\u00e9sultats prometteurs seul et en combinaison sur plusieurs types de tumeurs solides.<\/p>\n<p>Cette lev\u00e9e de fonds est l&#8217;une des plus importantes de l&#8217;ann\u00e9e pour une biotech. Seule Verdiva Bio a fait mieux avec 410 millions de dollars lev\u00e9s en janvier 2025. Verdiva a lanc\u00e9 trois traitements, dont un agoniste GLP-1 oral hebdomadaire, en collaboration avec Sciwind Biosciences de Chine.<\/p>\n<p>Fond\u00e9e en 2019, Eikon a pr\u00e9c\u00e9demment lev\u00e9 106 millions de dollars en 2023, totalisant 1,1 milliard de dollars d\u2019investissements. Co-fond\u00e9e par le laur\u00e9at du prix Nobel Eric Betzig, la soci\u00e9t\u00e9 utilise la microscopie \u00e0 super-r\u00e9solution et l&#8217;intelligence artificielle pour suivre les mouvements des prot\u00e9ines dans les cellules vivantes, une technologie qui pourrait influencer les futurs essais cliniques.<\/p>\n<p>Eikon d\u00e9veloppe aussi deux autres traitements en phase I : EIK1003, un inhibiteur s\u00e9lectif de PARP1 pour traiter certains cancers comme ceux du sein et de l&#8217;ovaire, et EIK1004, un inhibiteur p\u00e9n\u00e9trant le syst\u00e8me nerveux central pour le cancer du cerveau, avec des essais pr\u00e9vus pour 2025.<\/p>\n<p>La soci\u00e9t\u00e9 travaille \u00e9galement sur deux antagonistes des r\u00e9cepteurs aux androg\u00e8nes et un inhibiteur appel\u00e9 EIK1005, pour les cancers avec instabilit\u00e9 microsatellitaire et d&#8217;autres d\u00e9ficiences de r\u00e9paration de l&#8217;ADN.<\/p>\n<p>Parmi les investisseurs figurent Lux Capital, Alexandria Venture Investments, et Soros Capital.<\/p>\n<p>Inscrivez-vous \u00e0 notre revue quotidienne pour rester inform\u00e9 !<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le principal candidat d&#8217;Eikon, EIK1001, est en cours d&#8217;\u00e9tude pour traiter le m\u00e9lanome en combinaison avec Keytruda de MSD dans un essai clinique de Phase III.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-69585","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=69585"}],"version-history":[{"count":0,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69585\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=69585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=69585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=69585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}